A synergistic combination treatment plan that includes sorafenib at low doses, to decrease its toxicity, along with an anti-VEGF, anti-EGFR or an anti-VEGFR2 could result in a better cytotoxic effect in case of HCC. The gene discussed is EGFR; the disease is hepatocellular carcinoma.